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Abstract: 
The European LeukemiaNet (ELN) classification is widely accepted for risk stratification of patients with acute 
myeloid leukemia (AML). In order to establish immunophenotypic features that predict prognosis, the 
expression of single AML blast cell antigens has been evaluated with partly conflicting results; however, the 
influence of immunophenotypic blast maturity is largely unknown.  
In our study, 300 AML patients diagnosed at our institution between 01/2003 and 04/2012 were analyzed. A 
flow cytometric maturity score was developed in order to distinguish “mature” AML (AML-ma) from 
“immature” AML (AML-im) by quantitative expression levels of early progenitor cell antigens (CD34, CD117, 
and TdT).  
AML-ma showed significantly longer relapse-free survival (RFS) and overall survival (OS) than AML-im 
(p<0.001). Interestingly, statistically significant differences in RFS and OS were maintained within the 
“intermediate risk” group according to ELN (RFS: 7.0 years (AML-ma) vs. 3.3 years (AML-im); p=0.002; OS: 
5.1 years (AML-ma) vs. 3.0 years (AML-im); p=0.022).  
Our novel flow cytometric score easily determines AML blast maturity and can predict clinical outcome. It 
remains to be clarified whether these results simply reflect an accumulation of favorable molecular phenotypes 
in the AML-ma subgroup or whether they rely on biological differences such as a higher proportion of leukemia 
stem cells and/or a higher degree of genetic instability within the AML-im subgroup.  
 
 
Introduction 
Acute myeloid leukemia (AML) is a malignant haematopoietic neoplasm mainly occurring in elderly patients 
≥65 years of age [1]. Cytogenetic and molecular genetic abnormalities are thought to drive clonal expansion of 
early haematopoietic progenitor cells, which leads to rapid progressive suppression of normal bone marrow 
haematopoiesis. Subsequently, patients suffering from AML develop symptoms attributed to granulocytopenia, 
anaemia, and thrombocytopenia [2]. Besides age, cytogenetic and molecular features are the main prognostic 
factors that influence survival [3,4]. Hence, in 2009 the European LeukemiaNet (ELN) proposed a standardized 
reporting system that risk stratifies patients according to their genetic subgroup. As of today, it is well 
established for early prognostic assessment in AML patients [5,4,6,7,3,8-10]. Thus, patients in this cohort were 
primarily grouped according to these criteria [5].   
In addition to conventional cytogenetics and molecular genetics, flow cytometric analysis of blast cells plays an 
essential role in diagnosing AML. The prognostic significance of the expression of particular antigens remains 
controversial with previous studies mostly focusing on single antigens [11-14]. In contrast, the influence of 
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immunophenotypic maturity of AML blasts on overall prognosis is largely unknown. This is the first study using 
a quantitative score, consisting of three routinely used early progenitor cell markers for the assessment of AML 
blast maturity. The study was conducted to determine the influence of blast maturity on clinical parameters such 
as complete/incomplete remission after induction (CR/CRi), relapse-free survival (RFS), and overall survival 
(OS) both in the whole cohort and within the different risk groups according to ELN.  
 
Patients and Methods 
Patients 
Patients included in this study were ≥18 years and newly diagnosed with AML at the Charité University Medical 
Center Berlin, Campus Virchow Klinikum, from 01/2003 through 04/2012. Only patients with available flow 
cytometry report from our institution were included. AML-related data and patient demographics were collected 
for each patient. These included morphologic findings, conventional cytogenetics, molecular genetics (FLT3, 
NPM1, and MLL), blood count, type of treatment, date of CR/CRi as well as date of relapse, stem cell 
transplantation and death (Table 1).The retrospective study was performed after informed consent for bone 
marrow diagnostics and was in accordance with the local ethical guidelines.  
 
Flow cytometric analysis 
Of the 300 patients eligible for this study, flow cytometric analysis of bone marrow (n=284) or peripheral blood 
(n=16) was performed. EDTA samples were obtained and subsequently incubated with fluorochrome-labeled 
antibodies (FITC, PE, PC5.5, or APC) for the detection of cell surface antigens (CD1a, CD2, CD3, CD4, CD5, 
CD7, CD7.1/NG2, CD8, CD10, CD11b, CD11c, CD13, CD14, CD15, CD19, CD20, CD22, CD33, CD34, 
CD36, CD38, CD56, CD64, CD65, CD117, CD133, CD235a, HLA-DR) and intracytoplasmatic antigens (MPO, 
TdT, LF, cyCD3, cyCD22, cyCD79a) using BD FACSCalibur or BD FACSCantoTM systems (Becton, Dickinson 
and Company, San Jose, CA, USA). BD FACSDivaTM or BD CellQuestTM software was used for analysis of flow 
cytometry data. The blast cell population was identified by CD45/side scatter (SSC) gating of at least 30,000 
cells. Antigen expression was considered positive when ≥20% (surface antigens) or ≥10% (intracellular 
antigens) gated cells were positive. 
 
AML maturity score 
To classify AML according to the degree of maturity, a score based on the quantitative expression of CD34, 
CD117 and TdT was developed. All three markers are clearly associated with immaturity, can easily be 
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quantified, and had been evaluated over the whole study period [15]. The maturity score was weighed towards 
CD34 and TdT, since these markers show a particularly strong correlation with immaturity. As shown in Table 
2a, a score of 5 indicates maximal immaturity and a score of 0 indicates maturity. Table 2b shows the 
distribution of patients within the different “maturity groups”. A cut-off value of <1.5 points was the strongest 
discriminator with regard to RFS and OS (p<0.001, respectively) as determined by Kaplan-Meier survival 
curves. The cut-off value was not determined by the standardized median-split method, as the cut-off value of 
<1.5 points was a stronger discriminator with regard to RFS and OS. The purpose of this classification was to 
achieve a factor variable with two groups that can be used to describe the influence of the immaturity on the RFS 
and OS within a Kaplan-Meier-Analysis based on the developed score. 
Consequently, 109 patients (39.5%) were assigned to the “mature” group (0-1 points; “AML-ma”) and 167 
patients (60.5%) to the “immature” group (1.5-5 points, “AML-im”). The maturity score showed a good 
correlation with morphological maturity according to the FAB classification (data not shown).  
Data collection was performed using IBM SPSS Statistics®, version 20 (IBM® 2011, Armonk, NY, USA). 
Clinical parameters were CR/CRi, defined as bone marrow blasts <5% with or without blood count recovery 
after induction therapy, RFS and OS [5]. Survival characteristics were analyzed by means of the Kaplan Meier 
method. Differences were determined by the Chi Square and Fisher’s Exact Test (CR/CRi) and the Log rank test 
(RFS, OS). A p-value of p<0.05 was considered significant.   
 
Results 
Patients’ characteristics 
The baseline characteristics of the patients are given in Table 1. Median age at diagnosis was 61 years with a 
male predominance. Cytogenetic abnormalities were detected in n=170/273 patients (62.3%). Molecular genetic 
alterations (NPM1, FLT3, MLL) were found in n=92/256 patients (35.9%). Patients with incomplete cytogenetic 
results or mixed phenotype leukemias (n=53) were excluded from the analysis within the different ELN risk 
groups. Hence, we were able to assign 247/300 patients to an ELN risk group. The mean follow-up of all patients 
was 29.4 months (range 0-116.5 months). 206 of 300 (69%) patients reached CR/CRi after induction 
chemotherapy. In patients <60 years of age (n=141/300), the CR/CRi rate was 81.6% vs. 57.2% in patients ≥60 
years (n=159/300), (p<0.001). Mean RFS was 69.5 months with a higher RFS in patients <60 years (76.9 months 
vs. 58.5 months in patients ≥60 years), (p=0.057, Fig 1a). Mean OS was determined to be 46.7 months, being 
significantly longer in patients <60 years (61.0 months) compared to patients ≥60 years (33.7 months), (p<0.001, 
Fig 1b).  
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Immunophenotypic maturity and clinical outcome   
In 276 of 300 patients (92%) the maturity score could be determined. In 24 of 300 patients, flow cytometric 
analysis did not include all necessary parameters for the calculation of the novel maturity score. Regarding the 
CR/CRi rate, a tendency towards higher CR/CRi rates was observed in AML-ma (AML-ma: 73.4% vs. AML-im: 
64.1%, p=0.115), however, this was not statistically significant, neither in the group as a whole nor in subgroups 
divided by age, <60 years vs. ≥60 years (data not shown).  
In contrast, AML-ma showed a significantly longer mean RFS (89.4 months) when compared to AML-im (51.5 
months), (p<0.001). This difference was consistently found both in the whole cohort and in the age-related 
subgroups: In patients <60 years, the mean RFS was 92.1 months for AML-ma patients and 58.4 months for 
AML-im patients) (p=0.005) (Fig 2a). In patients ≥60 years, RFS was 82.7 months for patients with AML-ma vs. 
42.2 months for AML-im patients (p=0.01) (Fig 2b). 
Regarding OS, patients in the AML-ma group had a longer mean OS (63.8 months) than patients in the AML-im 
group (32.9 months) (p<0.001). Again, this difference was consistently observed both in the whole cohort and in 
age-related subgroups (AML patients <60 years: p<0.001 and AML patients ≥60 years: p=0.033) (Fig 2c,d). 
 
Influence of immunophenotypic maturity on clinical parameters within the different ELN risk groups  
In order to further evaluate our immunophenotypic maturity score, the patients were categorized according to the 
ELN risk groups. The subdivision of the intermediate ELN risk group into “intermediate 1“ and “intermediate 2“ 
has so far been controversial. Therefore, we combined these two groups into one intermediate risk group. Thus, 
adequate patient numbers within the three different groups were obtained.  In our AML cohort, the following risk 
groups according to ELN were determined: favorable risk (n=45), intermediate risk (n=132), and adverse risk 
(n=70). Within these different risk groups according to ELN, clinical parameters such as CR/CRi rate, RFS, and 
OS were consistent with the published literature [5]. In the ELN subgroups “favorable” vs. “intermediate” vs. 
“adverse”  CR/CRi rates were 86.7% vs. 78.0% vs. 55.7% (p<0.001), RFS was 93.8 months vs. 62.5 months vs. 
53.1 months (p=0.002) and OS was 77.5 months vs. 49.7 months vs. 28.0 months (p<0.001) (data not shown).  
Subsequently, the influence of our novel maturity score was evaluated within the ELN subgroups with regard to 
clinical parameters such as CR/CRi rate, RFS, and OS. Fig 3 shows the distribution of our AML cohort within 
the different ELN risk groups.  
Within the defined ELN risk groups, AML-ma showed higher CR/CRi rates than the AML-im patients. 
However, these differences did not reach statistical significance (data not shown). Regarding survival, in the 
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“favorable risk” group a longer RFS was observed in patients with AML-ma as compared to AML-im (102.5 
months vs. 83.7 months), however, this difference was not statistically significant (p=0.214) (Fig 4a). In contrast, 
in the “intermediate risk” group, which was the largest in our cohort, a highly significant difference in RFS in 
favor of the AML-ma subgroup was observed (84.5 months vs. 39.7 months, p=0.002) (Fig 4c). In the “adverse 
risk” group, no difference could be observed (data not shown).  
Furthermore, a longer OS in AML-ma patients as compared to AML-im patients could be observed across all 
ELN risk groups. However, this difference in OS reached statistical significance only in the “intermediate” risk 
group (AML-ma 61.4 months vs. 35.6 months, p=0.022) (Fig 4b).  
In order to exclude that these differences were caused by an imbalance of patients who had undergone allogeneic 
bone marrow transplantation (n=77/276), the analyses were repeated for all patients who had not been 
transplanted (n=223/276). Nevertheless, the differences in RFS and OS were maintained after exclusion of 
patients who had undergone allogeneic stem cell transplantation.  
 
Biological phenotype in maturity groups and ELN subgroups 
In order to further characterize the subgroup of AML patients who were categorized as AML-ma and AML-im 
according to our maturity score, we analyzed the frequency of cytogenetic and molecular aberrations in both 
subgroups. In the AML-ma subgroup we found a significant accumulation of PML-RARA and NPM1mut (ELN 
subgroup “favorable risk”) and CN-AML (ELN subgroup “intermediate risk”). In contrast, in the AML-im 
subgroup, there was a substantial accumulation of adverse phenotypes such as complex aberrant and monosomal 
karyotypes (ELN subgroup “adverse risk”). The differences are shown in Table 3. 
 
Discussion 
To the best of our knowledge, this is the first study evaluating AML blast maturity by means of a quantitative 
flow cytometric score in order to predict clinical outcome. We were able to show that a mature AML blast 
immunophenotype (AML-ma) was associated with a significantly longer RFS and OS than an immature 
immunophenotype (AML-im), (p<0.001). This was at least partly attributable to an accumulation of “low-risk” 
AML phenotypes such as NPM1mut and PML-RARA in the AML-ma group. “High-risk” aberrations (monosomal 
and complex aberrant karyotypes, -5 or del(5q), -7) had a higher frequency in the immature subgroup (see Table 
3).  
However, the differences in RFS and OS were maintained in a subgroup analysis within the different ELN risk 
groups. Statistical significance was only obtained in the “intermediate risk” group according to ELN with AML-
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ma being superior to AML-im with regard to RFS (p=0.002) and OS (p=0.022). No statistical significance could 
be observed in the favorable and adverse risk groups, possibly due to lower patient numbers in these subgroups. 
Although there was a trend towards better CR/CRi rates within the AML-ma subgroup, these differences were 
not statistically significant.  
The median age at first diagnosis of AML was 61 years in our patient cohort and is somewhat lower than 
reported in the literature (median about 67 years) [1]. This might explain, why our 5-year overall survival rate of 
38.3% is higher than in previously published reports such as the US cancer registry (24.9%) [1]. A Swedish 
registry study showed a decrease in 5-year overall survival with every 5-years of age increase (<50 years: 51%, 
50-54 years: 40%, 55-59 years: 23%, 60-64 years: 23%, 65-69 years: 13%, 70-74 years: 5%, 75-79 years: 3%, 
80-84 years: 2%, ≥85 years: 0%) [16].  
Additionally, our study included only patients with a comprehensive flow cytometric report, thereby indirectly 
excluding patients not suitable for intensive treatment since in those patients initial diagnostics are often 
restricted to morphologic evaluation. The monocentric design of the study at a large university center further 
enhances a selection bias towards younger patients in good clinical condition. 
The assignment to the different ELN risk groups was determined by cytogenetic and molecular data. During the 
study period, routine molecular genetic analyses performed in AML patients at initial diagnosis have become 
more and more comprehensive, whereas these analyses were performed with lower frequency and contained less 
molecular markers at the beginning of the study period. This may explain the lower frequency of molecular 
aberrations observed in our study as compared with the literature. Furthermore, many molecular aberrations 
which may impact clinical outcome (such as c-kit, DNMT3A and IDH mutations) have not been analyzed and – 
more importantly – are not yet integrated in the ELN risk stratification. It is very likely that the possible 
underestimation of molecular phenotypes in the current ELN risk classification in combination with a lack of 
data concerning particular molecular phenotypes has affected the risk classification within our study, particularly 
within the CN-AML group. However, this is an inherent limitation of AML risk stratification at a certain point in 
time and it certainly does not diminish our main conclusion that AML blast maturity does impact clinical 
outcome, irrespective of the underlying causes. 
However, having said this, there is no reason to assume a systematic bias towards a better or an inferior survival 
which has influenced our main conclusion concerning AML maturity.  
For the first time, our study shows a combined quantitative analysis of early progenitor markers in AML. The 
particular marker combination was chosen because it is 1) widely used, 2) allows for an easy quantification of 
the marker expression on AML blasts and 3) was continuously used throughout the study period. Although TdT 
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might be considered an unusual marker for AML, its correlation with blast immaturity is particularly strong [17]. 
We found that blast immaturity is correlated with particular phenotypes such as complex aberrations, monosomal 
karyotypes, accrual of chromosome 13 and a loss of chromosomes 5, 5q, and 7. In contrast, PML-RARA and 
NPM1 mutations had a higher frequency in the in the AML-ma group. These results are supported by previous 
studies, in which AML FAB M0 was associated an accumulation the same adverse chromosomal aberrations, a 
higher age and consequently a worse outcome [18-20]. Furthermore, also in recently published studies, a lower 
frequency of favorable molecular aberrations such as NPM1 and CEBPA has been described in the more 
immature AML subgroup AML FAB M0 [21]. Finally, the expression of CD34 in NPM1- and FLT3-ITD-
mutated AML seems to be associated with a worse clinical outcome [22,23] and it was recently reported that 
CD34 expression has negative impact in patients with acute promyelocitic leukemia [24].  
Apparently, all these results give rise to the question whether AML maturity is only a surrogate parameter for 
more favorable phenotypes or whether there is possibly also a causative biological relationship between maturity 
and a more favorable outcome. 
Within a category of more biological explanations, a higher genetic instability due to higher proliferation rates in 
immature cells might account for a higher probability of further genetic aberrations causing “clonal evolution” 
towards a more aggressive genotype with increasing resistance to therapy [25-27].  
Another hypothetical biological explanation is related to an increasing frequency of leukemic stem cells (LSC) 
within immature AML. Since these LSC – particularly in their dormant stage – may survive treatment and give 
rise to subsequent relapse [19,28-39]. The latter idea is supported by a recent study showing that a higher level of 
putative CD34+/CD38--LSC is associated with a worse prognosis [40].  
In conclusion, our novel flow cytometric AML maturity score allows for a prognostic stratification of newly 
diagnosed AML and gives additional prognostic information particularly in the intermediate risk group 
according to ELN. Within the ELN intermediate risk group, our maturity score might be an additional tool for 
choosing the most appropriate (risk-adapted) post remission therapy, particularly in those patients with a high 
overall transplantation-associated risk.  Furthermore, the flow cytometric score may be helpful in cases, in which 
cytogenetic and/or molecular data for prognostic stratification are not available. Nevertheless, before routine use, 
our score should be evaluated in another large AML cohort.  
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mature AML (AML-ma) and immature AML (AML-im) are depicted  
 
 
 
 
Table 1. Baseline characteristics of the 300 patients included in the study. 
No. of patients 300 
No. of female/male patients 139/161 
Median age at diagnosis (range), in years 61 (18 – 90) 
Cytogenetics (n/273) No. of patients (%) 
• Cytogenetically normal AML 103 (37.7%) 
• Complex-aberrant karyotype 46 (16.8%) 
• Monosomal karyotype 35 (12.8%) 
• Trisomy 8 31 (11.4%) 
• Deletion 7 30 (11.0%) 
• Deletion 5q 24 (8.8%) 
• Deletion 7q 15 (5.5%) 
• Inv(16) 9 (3.5%) 
• t(8;21) 7 (2.7%) 
Molecular genetics (n/256)  
• FLT3-ITDmut 32 (12.5%) 
• NPM1mut 28 (10.9%) 
• MLLmut 12 (4.7%) 
• FLT3-TKDmut 3 (1.2%) 
WHO classification of AML (2008)  
• AML with recurrent genetic abnormalities 65 (21.7%) 
• AML with myelodysplasia-related changes 73 (24.3%) 
• Therapy-related myeloid neoplasms 5 (1.7%) 
• AML, not otherwise specified  144 (48.0%) 
• Acute leukemias of ambiguous lineage 13 (4.3%) 
 
Table 2a. AML maturity score. According to quantitative antigen expression, acute 
myeloid leukemias were either classified as “immature” (high score, 1.5-5 points ) or 
“mature” (low score, 0-1 points).  
Antigen Expression (%) “Maturity Score“ (Points) 
CD34 
0-19 
20-49 
≥50 
0 
1 
2 
CD117 
0-19 
20-49 
≥50 
0 
0.5 
1 
TdT 
0-9 
10-49 
≥50 
0 
1 
2 
 
Table 2b. Distribution of patients in the different groups of the “maturity score”. 
“Maturity Score“ (Points) No. of Patients Percentage (%) 
0 35 11.7 
0.5 20 6.7 
1 54 18.0 
1.5 36 12.0 
2 24 8.0 
2.5 11 3.7 
3 73 24.3 
3.5 3 1.0 
4 12 4.0 
4.5 2 0.7 
5 6 2.0 
Not fully available 24 8.0 
Total 300  
 
Table 3. Accumulation of cytogenetic and molecular genetic results in AML-ma and 
AML-im groups. 
AML-ma 
(n=109) 
AML-im 
(n=167) 
NPM1mut  
p<0.001 
Complex-aberrant karyotype 
p<0.001 
t(15;17)/PML-RARA 
p<0.001 
Monosomal karyotype 
p<0.001 
CN-AML 
p<0.001 
Deletion 5q 
p=0.001 
 
Monosomy 7 
p<0.001 
 




